GGrantIndex
← Search

Roswell Park Cancer Center Support Grant

$4,468,904P30FY2024CANIH

Roswell Park Cancer Institute Corp, Buffalo NY

Investigators

Linked publications, trials & patents

Trial NCT07082270Trial NCT06202066Trial NCT05589844Trial NCT05338905Trial NCT05292521Trial NCT05231122Trial NCT04607291Trial NCT04533542Trial NCT04530812Trial NCT04526587Trial NCT04379518Trial NCT04358315Trial NCT04348747Trial NCT04298606Trial NCT04290962Trial NCT04269213Trial NCT04231539Trial NCT04207190Trial NCT04119830Trial NCT04110249Trial NCT04109924Trial NCT04093323Trial NCT04081389Trial NCT04073745Trial NCT04068649Trial NCT04067830Trial NCT04060446Trial NCT04032418Trial NCT04000581Trial NCT03965234Trial NCT03935347Trial NCT03899987Trial NCT03897270Trial NCT03895918Trial NCT03881735Trial NCT03880422Trial NCT03879694Trial NCT03865472Trial NCT03851081Trial NCT03793907Trial NCT03789877Trial NCT03751449Trial NCT03751436Trial NCT03736720Trial NCT03735589Trial NCT03735095Trial NCT03727789Trial NCT03727061Trial NCT03709550Trial NCT03691376Trial NCT03688945Trial NCT03685695Trial NCT03683147Trial NCT03680235Trial NCT03679585Trial NCT03679559Trial NCT03678350Trial NCT03630601Trial NCT03574792Trial NCT03457142Trial NCT03403634Trial NCT03384836Trial NCT03358719Trial NCT03348748Trial NCT03333486Trial NCT03297489Trial NCT03211416Trial NCT03206047Trial NCT03192397Trial NCT03090412Trial NCT03017131Trial NCT03011736Trial NCT02965976Trial NCT02955290Trial NCT02953457Trial NCT02947386Trial NCT02877641Trial NCT02857374Trial NCT02853318Trial NCT02833506Trial NCT02713373Trial NCT02650986Trial NCT02575885Trial NCT02575508Trial NCT02531906Trial NCT02474095Trial NCT02455557Trial NCT02452463Trial NCT02414724Trial NCT02399215Trial NCT02393755Trial NCT02334865Trial NCT02287727Trial NCT02227940Trial NCT02170389Trial NCT02166905Trial NCT02159950Trial NCT02119728Trial NCT02100254Trial NCT02072486

Abstract

Roswell Park Comprehensive Cancer Center (Roswell Park), established in 1898 is one of a small number of freestanding, NCI-designated, comprehensive cancer centers and the only comprehensive center in New York State (NYS) outside of Manhattan. The sole mission of the Center is to eliminate cancer's grip on humanity through cancer research, treatment, prevention and education. The Cancer Center which is in its 46th year of funding, is currently organized around 4 research programs, 9 shared resources, a clinical trial infrastructure that prioritizes investigator-initiated and innovative clinical trials that are a product of the research programs and a community outreach and engagement (COE), Cancer Research Training & Education Coordination (CRTEC) and Plan to Enhance Diversity (PED) that are interactive, cross-functioning and responsive to our catchment area. The Cancer Center supports 145 members and has recruited 162 new faculty since the previous review with 42 of them new members of the CCSG. Our cancer-relevant direct grant funding is currently $79M with 49% ($39M) coming from the NCI, a more than doubling of our NCI funding from 2018 with over 56% of funding in program/multi-PI type grants that underscores our commitment to collaborative research. Our high impact papers have increased to 29% from 10% in 2018 resulting in practice, paradigm and policy changing research. We have increased our focus on our community outreach and engagement, and we have an enhanced approach to our community and catchment area needs, especially with regard to diversity equity and inclusion. The Specific Aims over the next 5 years are as follows: Aim 1: Innovation: To be a leader in the development of innovative approaches in cancer research across basic, clinical and population sciences to improve the quality of care for our patients in our catchment area and beyond. Aim 2: Translation: To enhance collaborative efforts between basic, clinical and population scientists toward the more effective translation of our discoveries into paradigm changing patient practices and interventions and policies. Aim 3: Education: To train and develop the next generation of scientists and physicians through innovative oncology-focused programs that continue to develop translational opportunities across the clinic, the basic science and population science areas. Aim 4: Community: To ensure that the needs and priorities of communities in our catchment area are catalyzing high- impact science with a specific focus on strategies to promote health equity and drive rapid translation of scientific advances to reduce the cancer burden and related disparities in our catchment area and beyond. Aim 5: Equity & Inclusion: To cultivate, value and support diversity, equity, inclusion and belonging across our cancer center employees, scientists, physicians, nurses and healthcare staff, students and trainees and leadership toward a more productive and diverse workplace and to serve our community more effectively. Roswell Park continues to play a primary role in discovery and innovation in basic science findings that enable us to deliver the best cancer care to our patients in New York State, around the country and around the world.

View original record on NIH RePORTER →